Featured Research

from universities, journals, and other organizations

Epigenetic therapy shows promise in hard-to-treat lung cancer

Date:
November 9, 2011
Source:
American Association for Cancer Research
Summary:
Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to new data.

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

A research team at Johns Hopkins University tested a combination epigenetic therapy of azacitidine and entinostat among 45 patients with recurrent metastatic non-small cell lung cancer who had been heavily pretreated with other therapies but showed no response. Each patient received azacitidine on nine days and entinostat on two days per month. The trial had an "open-label" design, in which all patients received the treatment and there was no control group receiving a placebo.

Researchers found a median survival of 6.4 months with treatment, where the typical survival for this patient population is four months. Patients who showed signs of gene methylation reversal in at least two of four key genes had better survival than the rest, and two patients experienced dramatic tumor shrinkages.

Four of the 19 patients who received subsequent anticancer therapies had a major objective response to immediate subsequent treatment with other agents. Seven patients remain alive, including two who began treatment approximately four years ago.

"We are starting to show traction for epigenetic therapy for one of the most difficult-to-treat tumors," said Stephen A. Baylin, M.D., professor and deputy director of the Kimmel Cancer Center at Johns Hopkins University and leader of the Stand Up To Cancer (SU2C) Epigenetics Dream Team. "This study appears to show the first durable successes in solid tumors with epigenetic therapy."

This drug combination has previously shown efficacy among patients with leukemia.

"We hope these results lead to a larger, more definitive clinical trial of this drug combination," said Charles Rudin, M.D., Ph.D., professor of oncology and director of the Upper Aerodigestive Cancer Program at Hopkins' Kimmel Cancer Center. Rudin led the team of physicians and cancer biologists who conducted the study.

This research is funded in part by SU2C, a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) and the Flight Attendant Medical Research Institute.

"This research would not have been possible, especially at this accelerated pace, without Stand Up To Cancer," said Baylin. "Our SU2C Dream Team has benefitted enormously from the initiative's vision and visibility. The funding helps leverage other support mechanisms, like our SPORE grant from the NCI, which could never separately fund a trial of this magnitude and scope. It has enabled incredibly fruitful collaborations and allowed us, most importantly, to make a real difference in peoples' lives."

Portions of this release have been provided by Johns Hopkins.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. A. Juergens, J. Wrangle, F. P. Vendetti, S. C. Murphy, M. Zhao, B. Coleman, R. Sebree, K. Rodgers, C. M. Hooker, N. Franco, B. Lee, S. Tsai, I. E. Delgado, M. A. Rudek, S. A. Belinsky, J. G. Herman, S. B. Baylin, M. V. Brock, C. M. Rudin. Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer. Cancer Discovery, 2011; DOI: 10.1158/2159-8290.CD-11-0214

Cite This Page:

American Association for Cancer Research. "Epigenetic therapy shows promise in hard-to-treat lung cancer." ScienceDaily. ScienceDaily, 9 November 2011. <www.sciencedaily.com/releases/2011/11/111109111528.htm>.
American Association for Cancer Research. (2011, November 9). Epigenetic therapy shows promise in hard-to-treat lung cancer. ScienceDaily. Retrieved April 25, 2014 from www.sciencedaily.com/releases/2011/11/111109111528.htm
American Association for Cancer Research. "Epigenetic therapy shows promise in hard-to-treat lung cancer." ScienceDaily. www.sciencedaily.com/releases/2011/11/111109111528.htm (accessed April 25, 2014).

Share This



More Health & Medicine News

Friday, April 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Combination 'epigenetic' Therapy May Restore Anti-Cancer Gene Activity in Late-Stage Lung Cancer Patients

Nov. 10, 2011 A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial. Forty-five late-stage lung cancer patients who ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins